Evidence map›Paper›PMID 31937764›Full record

ArticleNature communications2020

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats.

Ellis Chika Onwordi, Els F Halff, Thomas Whitehurst, Ayla Mansur, Marie-Caroline Cotel, Lisa Wells, Hannah Creeney, David Bonsall, Maria Rogdaki, Ekaterina Shatalina and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 12 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 12 syntheses or guidelines pooled it, 229 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. First-in-Human Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Ellis Chika OnwordiPsychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK.
Els F HalffDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.ORCID http://orcid.org/0000-0001-5814-0899
Thomas WhitehurstPsychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK.
Ayla MansurDivision of Brain Sciences, Imperial College London, The Commonwealth Building, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Marie-Caroline CotelDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK.
Lisa WellsInvicro Imaging Services, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK.
Hannah CreeneyDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK.
David BonsallInvicro Imaging Services, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK.
Maria RogdakiPsychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK.ORCID http://orcid.org/0000-0003-2685-1789
Ekaterina ShatalinaPsychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK.
Tiago Reis MarquesPsychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK.
Eugenii A RabinerInvicro Imaging Services, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK.
Roger N GunnDivision of Brain Sciences, Imperial College London, The Commonwealth Building, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Sridhar NatesanPsychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK.ORCID http://orcid.org/0000-0001-7499-1714
Anthony C VernonDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK.ORCID http://orcid.org/0000-0001-7305-1069
Oliver D HowesPsychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK. oliver.howes@lms.mrc.ac.uk.
King's College London · GBHammersmith Hospital · GBInvicro (United Kingdom) · GB

Funding

Medical Research Council G0700995Medical Research Council MC_U120097115Medical Research Council MR/L022176/1Medical Research Council MR/N025377/1Medical Research Council MR/N026063/1Medical Research Council MR/N027078/1
6 · The paper itself

Abstract

Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but this has not been tested directly in vivo.  Here, we investigated synaptic vesicle glycoprotein 2A (SV2A) levels and their relationship to symptoms and structural brain measures using [

Indexed as

AnimalsAntipsychotic AgentsBrainFemaleFrontal LobeGyrus CinguliHumansMaleMembrane GlycoproteinsNerve Tissue ProteinsOrgan SpecificityPositron-Emission TomographyPyridinesPyrrolidinonesRatsRats, Sprague-Dawley1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-oneAntipsychotic AgentsMembrane GlycoproteinsNerve Tissue ProteinsPyridinesPyrrolidinonesSV2A protein, human

Identifiers

PMID31937764
PMCPMC6959348
OpenAlexW2997938254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.